Related Experiment Video

Updated: Jun 16, 2026

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
05:37

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration

Published on: May 31, 2018

Potential role of caveolin-1 in acetaminophen-induced hepatotoxicity

Carol R Gardner1, Joshua P Gray, Laurie B Joseph

  • 1Department of Pharmacology and Toxicology, Rutgers University, Ernest Mario School of Pharmacy, Piscataway, NJ 08854, USA. cgardner@eohsi.rutgers.edu

Toxicology and Applied Pharmacology
|January 27, 2010
PubMed

Insights

Caveolin-1 (Cav-1) protein promotes liver injury from acetaminophen overdose. Mice lacking Cav-1 showed reduced liver damage, indicating Cav-1

Area of Science:

  • Hepatology
  • Molecular Biology
  • Toxicology

Background:

  • Caveolin-1 (Cav-1) is a key membrane scaffolding protein regulating intracellular signaling.
  • Acetaminophen overdose is a leading cause of acute liver injury.
  • The specific role of Cav-1 in acetaminophen-induced hepatotoxicity remains unclear.

Purpose of the Study:

  • To investigate the role of Cav-1 in the pathogenesis of acetaminophen-induced liver injury.
  • To determine if Cav-1 deficiency influences acetaminophen metabolism or toxicity.

Main Methods:

  • Utilized Cav-1 knockout (Cav-1(-/-)) and wild-type (WT) mice.
  • Administered acetaminophen (300 mg/kg) to induce hepatotoxicity.
  • Assessed liver damage via hepatic necrosis and serum transaminases.
  • Measured oxidative stress markers (lipocalin 24p3, hemeoxygenase-1, glutathione, SOD-1).
  • Quantified inflammatory cytokine and enzyme expression (IL-1β, MCP-1, COX-2, 15-LOX, TNF-α).
  • Evaluated cellular proliferation markers (PCNA, survivin).

Main Results:

  • Acetaminophen caused significant liver necrosis and elevated transaminases in WT mice.
  • Cav-1(-/-) mice exhibited significantly attenuated acetaminophen-induced hepatotoxicity.
  • Reduced toxicity in Cav-1(-/-) mice was independent of acetaminophen metabolism.
  • Oxidative stress markers showed no significant genotypic differences.
  • Acetaminophen altered inflammatory gene expression, with greater changes in MCP-1 and 15-LOX in Cav-1(-/-) mice.
  • While TNF-α was upregulated in Cav-1(-/-) mice, cellular proliferation markers were delayed, suggesting reduced repair needs.

Conclusions:

  • Cav-1 plays a critical role in promoting inflammation and toxicity during acetaminophen-induced liver injury.
  • Targeting Cav-1 may offer a therapeutic strategy for acetaminophen overdose.

More Related Videos

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...